Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals Inc (MIST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 162,380
  • Shares Outstanding, K 117,667
  • Annual Sales, $ 1,550 K
  • Annual Income, $ -63,060 K
  • EBIT $ -64 M
  • EBITDA $ -64 M
  • 60-Month Beta 0.69
  • Price/Sales 99.70
  • Price/Cash Flow N/A
  • Price/Book 3.33

Options Overview Details

View History
  • Implied Volatility 516.90% (+341.52%)
  • Historical Volatility 109.71%
  • IV Percentile 97%
  • IV Rank 76.42%
  • IV High 652.40% on 03/30/26
  • IV Low 77.80% on 01/21/26
  • Expected Move (DTE 14) 0.2125 (15.40%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 406
  • Volume Avg (30-Day) 1,428
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 49,547
  • Open Int (30-Day) 49,762
  • Expected Range 1.1675 to 1.5925

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.01
  • Number of Estimates 3
  • High Estimate $0.50
  • Low Estimate $-0.28
  • Prior Year $-0.31
  • Growth Rate Est. (year over year) +103.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +38.00%
on 03/30/26
1.7900 -22.91%
on 03/17/26
-0.3500 (-20.23%)
since 03/02/26
3-Month
1.0000 +38.00%
on 03/30/26
2.2700 -39.21%
on 01/08/26
-0.6700 (-32.68%)
since 01/02/26
52-Week
0.6300 +119.05%
on 04/09/25
3.0600 -54.90%
on 12/12/25
+0.5800 (+72.50%)
since 04/02/25

Most Recent Stories

More News
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity...

MIST : 1.3800 (+5.34%)
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 1.3800 (+5.34%)
Milestone Pharmaceuticals: Q4 Earnings Snapshot

Milestone Pharmaceuticals: Q4 Earnings Snapshot

MIST : 1.3800 (+5.34%)
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT Participants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic...

MIST : 1.3800 (+5.34%)
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 1.3800 (+5.34%)
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report fourth quarter and full-year 2025 results and provide...

MIST : 1.3800 (+5.34%)
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief...

MIST : 1.3800 (+5.34%)
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance...

MIST : 1.3800 (+5.34%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 1.3800 (+5.34%)
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially insured...

MIST : 1.3800 (+5.34%)

Business Summary

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 1.5933
2nd Resistance Point 1.4967
1st Resistance Point 1.4383
Last Price 1.3800
1st Support Level 1.2833
2nd Support Level 1.1867
3rd Support Level 1.1283

See More

52-Week High 3.0600
Fibonacci 61.8% 2.1317
Fibonacci 50% 1.8450
Fibonacci 38.2% 1.5583
Last Price 1.3800
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.